TOVX Theriva Biologics Inc: Enterprise Value-to-Revenue Multiple

Public company logo of therivabio.com (TOVX)

Theriva Biologics, Inc. (TOVX) conducts proprietary clinical trials of oncolytic viruses, limiting its partnerships to research centers. Such alliances create scientific synergy, enhancing the attractiveness of assets for future M&A transactions. The firm's revenues are based on grants aimed at developing treatments for solid tumors. The business valuation relative to revenue illustrates fundamental stability, where the 1566.67 indicator determines the magnitude of the metric.

Company Value to Revenue: Theriva Biologics Inc (TOVX) for 11/23/2025 - 11/21/2026

therivabio.com - analytical breakdowns and key metrics (TOVX)

- share price and consensus valuation forecast:
Initial company analysis:Theriva Biologics, Inc. TOVX
Product sample of Theriva Biologics, Inc.

Valuing Theriva Biologics, Inc. (TOVX) using the EV/Revenue multiple allows for the determination of the business's market price accounting for net debt, thereby eliminating the impact of capital structure on fundamental value. By analyzing EV/Sales dynamics, an investor can gauge the extent of asset overvaluation given the company's critical dependence on clinical trial outcomes and liquidity shortage risks within the highly competitive oncopharmaceuticals sector.

Competitor analysis for Theriva Biologics, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP